| Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over | TA1051 | | |
| Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (terminated appraisal) | TA1052 | | |
| Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable | TA1048 | | |
| Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia | TA1049 | | |
| Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over | TA1050 | | |
| Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma | TA1046 | | |
| Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal) | TA1047 | | |
| 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites | TA1045 | | |
| Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection | TA1043 | | |
| Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over | TA1044 | | |
| Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer | TA1041 | | |
| Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer | TA1042 | | |
| Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over | TA1033 | | |
| Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over | TA1038 | | |
| Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over | TA1039 | | |
| Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy | TA1040 | | |
| Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer | TA1037 | | |
| Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment | TA1036 | | |
| Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease | TA1035 | | |
| Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer (terminated appraisal) | TA1032 | | |
| Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours | TA1034 | | |
| Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over | TA1031 | | |
| Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal) | TA1028 | | |
| Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal) | TA1029 | | |
| Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer | TA1030 | | |
| Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban | TA697 | | |
| Tebentafusp for treating advanced uveal melanoma | TA1027 | | |
| Tirzepatide for managing overweight and obesity | TA1026 | | |
| Ublituximab for treating relapsing multiple sclerosis | TA1025 | | |
| Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments | TA1023 | | |
| Toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer (terminated appraisal) | TA1024 | | |
| Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer | TA1021 | | |
| Bevacizumab gamma for treating wet age-related macular degeneration | TA1022 | | |
| Eplontersen for treating hereditary transthyretin-related amyloidosis | TA1020 | | |
| Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer | TA1017 | | |
| Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis | TA1018 | | |
| Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over | TA1019 | | |
| Elafibranor for previously treated primary biliary cholangitis | TA1016 | | |
| Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer | TA1014 | | |
| Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments | TA1015 | | |
| Avapritinib for treating advanced systemic mastocytosis | TA1012 | | |
| Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria | TA1010 | | |
| Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia | TA1013 | | |
| Belzutifan for treating tumours associated with von Hippel-Lindau disease | TA1011 | | |
| Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension | TA1009 | | |
| Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments | TA1008 | | |
| Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer | TA1007 | | |
| Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) | TA1006 | | |
| Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over | TA1002 | | |
| Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over | TA1003 | | |